EGFR and cutaneous mastocytosis: To provide supportive evidence that the above reported observations could be potentially effective also in vivo in CM patients, we evaluated whether, in the presence of cetuximab, also PBMCs obtained from allogeneic metastatic CM patients were able to effectively kill ex vivo EGFR-positive VR CM cells through ADCC.